Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients (THAL-RID-BC)
Thalidomide for Prevention of Radiation-Induced Dermatitis in Breast Cancer Patients After Breast-Conserving Surgery Receiving Radiotherapy: A Randomized Controlled Study
To evaluate the efficacy and safety of oral thalidomide for the prevention of radiation-induced dermatitis (RID) in breast-conserving surgery patients receiving intensity-modulated whole-breast radiotherapy. This is a single-center randomized controlled trial. Female breast cancer patients aged >18 and <70 years after breast-conserving surgery scheduled for whole-breast intensity-modulated radiotherapy will be enrolled. Subjects will be randomized at a 1:1 ratio to the intervention group (thalidomide 75 mg orally every bedtime plus standard skin care) or the control group (standard skin care alone). The observation window is defined as from the start of first radiotherapy to 42 days after completion of last radiotherapy. RID will be assessed weekly according to CTCAE v5.0, and the maximum grade within the observation window will be recorded for each subject. The primary endpoint is the incidence of grade ≥2 RID within the observation window. Secondary endpoints include incidence of grade ≥3 RID, time-to-first-onset of grade ≥2 RID, RID-related symptoms (burning, pruritus, pulling pain, tenderness), quality-of-life measured by EORTC QLQ-C30 / QLQ-BR23. Treatment-emergent adverse events will be documented using CTCAE v5.0, with special attention to thalidomide-related toxicities such as somnolence, peripheral sensory neuropathy and thromboembolism. A total of 68 participants are planned for enrolment.
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习联系方式
学习联系方式
- 姓名：Zhendong Yang, MD
- 电话号码：+86 7715356509
- 邮箱：yangzhendong@stu.gxmu.edu.cn
学习地点
-
-
Guangxi
-
Nanning、Guangxi、中国、530011
- 招聘中
- The First Affiliated Hospital of Guangxi Medical University
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female patients with histopathologically confirmed breast cancer after breast-conserving surgery, no distant metastasis, scheduled for intensity-modulated radiotherapy (IMRT).
- Age greater than 18 years and less than 70 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Adequate laboratory examinations obtained within 14 days before enrolment (without prior blood transfusion): white blood cell (WBC) ≥3.0 × 10⁹/L, absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, platelet (PLT) ≥100 × 10⁹/L, hemoglobin (Hb) ≥90 g/L; total bilirubin (TBIL) ≤2.0 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5 × ULN, or creatinine clearance ≥60 mL/min calculated by the Cockcroft-Gault formula.
- No prior history of breast or chest-wall radiotherapy.
- For women of child-bearing potential: negative serum or urine pregnancy test within 72 hours prior to enrolment; fully informed of the teratogenic risk of thalidomide and agree to use dual effective contraception throughout study-drug administration and for 4 weeks after drug discontinuation; subjects refusing contraception are excluded. Post-menopausal women (amenorrhea for ≥12 consecutive months) do not require pregnancy testing.
- Fully informed of the study content, voluntarily provide written informed consent, and are able to complete radiotherapy, study medication, scheduled assessments and follow-up visits.
- For patients who received prior adjuvant chemotherapy: at least a 2-week interval between completion of chemotherapy and commencement of radiotherapy.
Exclusion Criteria:
- History of other malignant tumours (except cured in situ carcinoma).
- Psychiatric disorders or severe cognitive impairment that prevent subjects from completing questionnaires and assessments.
- Pregnant or lactating women.
- Poorly controlled diabetes mellitus (HbA1c > 7.5%); patients with well-controlled diabetes are eligible.
- Active autoimmune or rheumatic diseases (systemic lupus erythematosus, dermatomyositis, scleroderma, etc.); subjects with stable mild disease without systemic medication may be considered.
- Pre-existing or past history of peripheral neuropathy (numbness, tingling, paraesthesia); prior exposure to thalidomide, lenalidomide, pomalidomide; concomitant use of medications known to induce peripheral neurotoxicity.
- Past history of venous thromboembolism (VTE); hereditary thrombophilia; ongoing oestrogen-containing therapy.
- Severe cardiovascular and cerebrovascular diseases: myocardial infarction, unstable angina or stroke within the past 6 months; left ventricular ejection fraction (LVEF) < 50%.
- Pre-existing active eczema, psoriasis, chronic dermatitis, unhealed wounds or extensive scarring within the radiation field.
- Contraindications to radiotherapy.
- Known hypersensitivity to thalidomide or excipients of the preparation.
- Planned use of any additional oral or topical agents or dressings for prevention or treatment of radiation-induced dermatitis during study participation.
- Other conditions judged by the investigator making the subject unsuitable for this clinical trial.
学习计划
研究是如何设计的？
设计细节
- 主要用途：预防
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的：Thalidomide plus Standard Care Group
Patients receive oral thalidomide together with standard supportive care concurrently with breast cancer radiotherapy for the prevention of radiation dermatitis. |
Patients receive thalidomide 75 mg orally once every night at bedtime, starting from the first fraction of radiotherapy until completion of the last fraction of radiotherapy. All patients receive uniform standard skin care education and guidance for radiation field skin: wear loose fitting 100% cotton tops; avoid direct sunlight exposure to irradiated skin; keep irradiated skin dry, clean and well ventilated; avoid friction and scratching. |
|
有源比较器：Standard Care Control Group
Patients receive only standard supportive care during breast cancer radiotherapy, without thalidomide. |
All patients receive uniform standard skin care education and guidance for radiation field skin: wear loose fitting 100% cotton tops; avoid direct sunlight exposure to irradiated skin; keep irradiated skin dry, clean and well ventilated; avoid friction and scratching. |
研究衡量的是什么？
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of grade ≥2 acute radiation dermatitis
大体时间：From first radiation fraction to 42 days after completion of radiotherapy
|
Proportion of participants developing grade 2 or worse acute radiation dermatitis, assessed using CTCAE Version 5.0. |
From first radiation fraction to 42 days after completion of radiotherapy
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Patient-reported burning symptom of radiation-induced dermatitis
大体时间：Baseline to 42 days after completion of radiotherapy
|
Patient-reported severity of burning measured by a numeric rating scale (0-5; 0 = no symptom, 5 = worst imaginable symptom). Assessments are performed at baseline, weekly during radiotherapy, at the end of radiotherapy, and at 42 days after completion of radiotherapy. |
Baseline to 42 days after completion of radiotherapy
|
|
Patient-reported pruritus symptom of radiation-induced dermatitis
大体时间：Baseline to 42 days after completion of radiotherapy
|
Patient-reported severity of pruritus measured by a numeric rating scale (0-5; 0 = no symptom, 5 = worst imaginable symptom). Assessments are performed at baseline, weekly during radiotherapy, at the end of radiotherapy, and at 42 days after completion of radiotherapy. |
Baseline to 42 days after completion of radiotherapy
|
|
Patient-reported pulling pain symptom of radiation-induced dermatitis
大体时间：Baseline to 42 days after completion of radiotherapy
|
Patient-reported severity of pulling pain measured by a numeric rating scale (0-5; 0 = no symptom, 5 = worst imaginable symptom). Assessments are performed at baseline, weekly during radiotherapy, at the end of radiotherapy, and at 42 days after completion of radiotherapy. |
Baseline to 42 days after completion of radiotherapy
|
|
Patient-reported tenderness symptom of radiation-induced dermatitis
大体时间：Baseline to 42 days after completion of radiotherapy
|
Patient-reported severity of tenderness measured by a numeric rating scale (0-5; 0 = no symptom, 5 = worst imaginable symptom). Assessments are performed at baseline, weekly during radiotherapy, at the end of radiotherapy, and at 42 days after completion of radiotherapy. |
Baseline to 42 days after completion of radiotherapy
|
|
Health-related quality of life
大体时间：Baseline to 6 months after completion of radiotherapy
|
Health-related quality of life will be assessed using the EORTC QLQ-C30 questionnaires. Assessments are performed at baseline (before the first radiotherapy fraction), 42 days, 3 months and 6 months after completion of radiotherapy. A mixed-effects model will be used to analyse longitudinal changes in subscale scores. Changes from baseline in each subscale at 42 days, 3 months and 6 months after radiotherapy will be calculated and compared between groups. |
Baseline to 6 months after completion of radiotherapy
|
|
Health-related quality of life QLQ-BR23
大体时间：Baseline to 6 months after completion of radiotherapy
|
Health-related quality of life will be assessed using the QLQ-BR23 questionnaires. Assessments are performed at baseline (before the first radiotherapy fraction), 42 days, 3 months and 6 months after completion of radiotherapy. A mixed-effects model will be used to analyse longitudinal changes in subscale scores. Changes from baseline in each subscale at 42 days, 3 months and 6 months after radiotherapy will be calculated and compared between groups. |
Baseline to 6 months after completion of radiotherapy
|
|
Adverse events and serious adverse events
大体时间：From enrolment to at least 3 months after the last dose of study drug
|
Adverse events are graded according to CTCAE Version 5.0. Special attention will be paid to thalidomide-related toxicities, including somnolence, peripheral sensory neuropathy and venous thromboembolism. |
From enrolment to at least 3 months after the last dose of study drug
|
合作者和调查者
调查人员
调查人员
- 首席研究员：Zhendong Yang、First Affiliated Hospital of Guangxi Medical University
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- 2024-S908-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.